Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion

Brain Research

Volumn 1082, Issue 1, 2006, Pages 182-191

  Lee, Jeong Hyun ^a   Park, So Youn ^a   Shin, Yung Woo ^a   Hong, Ki Whan ^a,b   Kim, Chi Dae ^a,b   Sung, Sang Min ^c   Kim, Ki Young ^d   Lee, Won Suk ^a  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Busan Medical Center   (South Korea)

^d Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Chronic cerebral hypoperfusion; Cilostazol; Optic tract; TUNEL; White matter

Indexed keywords

CASPASE 3; CILOSTAZOL; DIMETHYL SULFOXIDE; PHOSPHODIESTERASE III INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CELL ACTIVATION; CELL COUNT; CELL VACUOLE; COMMON CAROTID ARTERY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; IMMUNOREACTIVITY; MALE; MICROGLIA; NEUROPROTECTION; NICK END LABELING; NONHUMAN; OLIGODENDROGLIA; OPTIC TRACT; PRIORITY JOURNAL; RAT; WHITE MATTER;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; CASPASE 3; CASPASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; NEUROGLIA; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; TETRAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS NORVEGICUS;

EID: 33645845665     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.01.088     Document Type: Article

References (28)

1. Akiguchi I., Tomimoto H., Suenaga T., Wakita H., and Budka H. Alterations in glia and axons in the brains of Binswanger's disease patients. Stroke 28 (1997) 1423-1429
2. Boone K.B., Miller B.L., Lesser I.M., Mehringer C.M., Hill-Gutierrez E., Goldberg M.A., and Berman N.G. Neuropsychological correlates of white-matter lesions in healthy elderly subjects. A threshold effect. Arch. Neurol. 49 (1992) 549-554
3. Choi J.M., Shin H.K., Kim K.Y., Lee J.H., and Hong K.W. Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats. J. Pharmacol. Exp. Ther. 300 (2002) 787-793
4. Deutsch G., and Tweedy J.R. Cerebral blood flow in severity-matched Alzheimer and multi-infarct patients. Neurology 37 (1987) 431-438
5. Galvez A., Gimenez-Gallego G., Reuben J.P., Roy-Contancin L., Feigenbaum P., Kaczorowski G.J., and Garcia M.L. Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion Buthus tamulus. J. Biol. Chem. 265 (1990) 11083-11090
6. Hollensworth S.B., Shen C., Sim J.E., Spitz D.R., Wilsonn G.L., and LeDoux S.P. Glial cell type-specific responses to menadione-induced oxidative stress. Free Radic. Biol. Med. 28 (2000) 1161-1174
7. Hong K.W., Kim K.Y., Shin H.K., Lee J.H., Choi J.M., Kwak Y.G., Kim C.D., Lee W.S., and Rhim B.Y. Cilostazol prevents tumor necrosis factor-α-induced cell death by suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation and activation of Akt/cyclic AMP response element-binding protein phosphorylation. J. Pharmacol. Exp. Ther. 306 (2003) 1182-1190
8. Ihara M., Tomimoto H., Kinoshita M., Oh J., Noda M., Wakita H., Akiguchi I., and Shibasaki H. Chronic cerebral hypoperfusion induces MMP-2 but not MMP-9 expression in the microglia and vascular endothelium of white matter. J. Cereb. Blood Flow Metab. 21 (2001) 828-834
9. Kim K.Y., Shin H.K., Choi J.M., and Hong K.W. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J. Pharmacol. Exp. Ther. 300 (2002) 709-715
10. Kimura Y., Tani T., Kanbe T., and Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
11. Kurumatani T., Kudo T., Ikura Y., and Takeda M. White matter changes in the gerbil brain under chronic cerebral hypoperfusion. Stroke 29 (1998) 1058-1062
12. Lee J.H., Lee Y.K., Ishikawa M., Koga K., Fukunaga M., Miyakoda G., Mori T., Hosokawa T., and Hong K.W. Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats-An MRI study. Brain Res. 994 (2003) 91-98
13. Lee J.H., Kim K.Y., Lee Y.K., Park S.Y., Kim C.D., Lee W.S., Rhim B.Y., and Hong K.W. Cilostazol prevents focal cerebral ischemic injury by enhancing caseine kinase 2 phosphorylation and suppression of phosphatase and tensin homolog deleted from chromosome 10 phosphorylation in rats. J. Pharmacol. Exp. Ther. 308 (2004) 896-903
14. Pantoni L., Garcia J.H., and Gutierrez J.A. Cerebral white matter is highly vulnerable to ischemia. Stroke 27 (1996) 1641-1646
15. Park S.Y., Lee J.H., Kim Y.K., Kim C.D., Rhim B.Y., Lee W.S., and Hong K.W. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J. Pharmacol. Exp. Ther. 312 (2005) 1241-1248
16. Petito C.K., Olarte J.P., Roberts B., Nowak Jr. T.S., and Pulsinelli W.A. Selective glial vulnerability following transient global ischemia in rat brain. J. Neuropathol. Exp. Neurol. 57 (1998) 231-238
17. Sawada M., Kondo N., Suzumura A., and Marunouchi T. Production of tumor necrosis factor-α by microglia and astrocytes in culture. Brain Res. 491 (1989) 394-397
18. Schade F.U., and Schudt C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 230 (1993) 9-14
19. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., and Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109 (2004) 1022-1028
20. Suzumura A., Ito A., Yoshikawa M., and Sawada M. Ibudilast suppresses TNFα production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 837 (1999) 203-212
21. Tanaka K., Ogawa N., Asanuma M., Kondo Y., and Nomura M. Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion. Brain Res. 729 (1996) 55-65
22. Taupin V., Renno T., Bourbonniere L., Peterson A.C., Rodriguez M., and Owens T. Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-α in the central nervous system. Eur. J. Immunol. 27 (1997) 905-913
23. Tomimoto H., Akiguchi I., Wakita H., Kinoshita A., Ikemoto A., Nakamura S., and Kimura J. Glial expression of cytokines in the brains of cerebrovascular disease patients. Acta Neuropathol. 92 (1996) 281-287
24. Tomimoto H., Ihara M., Wakita H., Ohtani R., Lin J.X., Akiguchi I., Kinoshita M., and Shibasaki H. Chronic cerebral hypoperfusion induces white matter lesions and loss of oligodendroglia with DNA fragmentation in the rat. Acta Neuropathol. 106 (2003) 527-534
25. Wakita H., Tomimoto H., Akiguchi I., and Kimura J. Glial activation and white matter changes in the rat brain induced by chronic cerebral hypoperfusion: an immunohistochemical study. Acta Neuropathol. 87 (1994) 484-492
26. Wakita H., Tomimoto H., Akiguchi I., Lin J.X., Miyamoto K., and Oka N. A cyclooxygenase-2 inhibitor attenuates white matter damage in chronic cerebral ischemia. NeuroReport 10 (1999) 1461-1465
27. Wakita H., Tomimoto H., Akiguchi I., Lin J.X., Ihara M., Ohtani R., and Shibata M. Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat. Brain Res. 992 (2003) 53-59
28. 2+ Homeostasis by Bcl-2. J. Biol. Chem. 274 (1999) 33267-33273